b S Supporting Information P arkinson's disease is a common, debilitating neurodegenerative disease with no established therapy that targets the underlying molecular mechanisms of disease. Mutations in the protein kinase LRRK2 are associated with rare forms of autosomal dominant Parkinson's disease, and patients carrying LRRK2 mutations present with symptoms resembling idiopathic Parkinson's disease. 1, 2 Mutations inside (e.g., G2019S) and outside (e.g., R1441C) the kinase domain influence kinase activity and are linked to LRRK2-induced toxicity in vitro. 3 In vivo, overexpression of wild type LRRK2 alone does not cause neurodegeneration but greatly exacerbates the progression of neuropathological abnormalities observed in Parkinson's diseaserelated A53T R-synuclein transgenic mice. 4 Several inhibitors that display activity against LRRK2 but also against many other kinases have been identified. 5À8 Brain-penetrant, non-selective kinase inhibitors such as GW-5074 are protective in rodent models of LRRK2-induced neurodegeneration in vitro and in vivo, suggesting that LRRK2 inhibition could be a new treatment paradigm for Parkinson's disease. 7 However, the poor kinase selectivity of GW-5074 and its low potency toward LRRK2 raised the question of whether LRRK2 inhibition alone confers the observed neuroprotection. 9 Furthermore, GW-5074 exhibits a complex pharmacology as an allosteric glutamate dehydrogenase inhibitor 10 and an anti-polio virus (but not anti-Sendai virus) agent with a Raf1-independent mechanism of action. 11 Although neuroprotection by LRRK2 inhibition has been consistently shown in rodent models, similar effect in a human neuronal model has yet to be demonstrated. Recently, a selective LRRK2 inhibitor, LRRK2-IN-1, has been described, but it is unknown whether it blocks mutant LRRK2-induced toxicity in primary neurons. 12 Here we report the chemoproteomics-driven discovery of the first potent, selective LRRK2 inhibitors that attenuate toxicity in primary rodent and human neurons that is triggered by expression of mutant LRRK2.
To identify selective LRRK2 inhibitors binding to endogenous LRRK2 in tissue extracts, we adapted a chemical proteomics strategy previously used for target discovery and mechanism of action studies,
13À15 so that precise IC 50 measurements could be obtained to support a drug discovery project. 16 To this end, we made a linkable analogue of the ATP-competitive non-selective ABSTRACT: Leucine-rich repeat kinase-2 (LRRK2) mutations are the most important cause of familial Parkinson's disease, and non-selective inhibitors are protective in rodent disease models. Because of their poor potency and selectivity, the neuroprotective mechanism of these tool compounds has remained elusive so far, and it is still unknown whether selective LRRK2 inhibition can attenuate mutant LRRK2-dependent toxicity in human neurons. Here, we employ a chemoproteomics strategy to identify potent, selective, and metabolically stable LRRK2 inhibitors. We demonstrate that CZC-25146 prevents mutant LRRK2-induced injury of cultured rodent and human neurons with midnanomolar potency. These precise chemical probes further validate this emerging therapeutic strategy. They will enable more detailed studies of LRRK2-dependent signaling and pathogenesis and accelerate drug discovery.
kinase inhibitor sunitinib (la-sunitinib; Figure 1a and Supporting Information) and immobilized it on a solid-phase matrix. 6, 13 Under close to physiological conditions, this affinity matrix captured LRRK2 from mouse brain and kidney extracts (Figure 1b ). Binding and detection were specific, as no LRRK2-immunoreactive band was captured when tissue extracts from LRRK2 Figures S2 and S3 ). Mouse kidney (upper panels) or mouse brain (lower panels) extracts (5 mg) were preincubated with 30, 7.5, 1.88, 0.47, 0.12 μM free sunitinib (or vehicle control) (left panels) or S7 (right panels). Kinase targets not occupied by free test compounds were captured by la-sunitinib matrix. Proteins eluted from the matrix were quantified by chemical labeling of tryptic peptides with isobaric TMT tags, followed by tandem mass spectrometry analysis (LCÀMS/MS) of the combined peptide pools. ConcentrationÀresponse curves and IC 50 for LRRK2 were computed from the changes of reporter ion signals relative to the DMSO control for all sequenced peptides corresponding to LRRK2. An S7-affinity matrix displayed an improved signal-to-noise ratio in a dot-blot array assay format (Supplementary Figures S2 and S3 ) and was used for screening of 127 compounds against endogenous LRRK2 from mouse kidney. Figure S2) , we profiled several tissues and human cell lines. We identified higher levels of LRRK2 in kidney than in brain and observed expression of the kinase in heart, placenta, K562, and Ramos cells, but not in Jurkat, Molt-4, HL-60, or HeLa cells (Figure 1c and Supplementary Figure S1c ). This expression pattern is consistent with previously reported LRRK2 expression in human B (but not T) lymphocytes 17 and highlights the need for potent, selective LRRK2 chemical probes to interrogate its function in multiple Figure S2) . ConcentrationÀresponse curves for each compound were generated in three different lysates, HeLa, a Jurkat/Ramos mixture, and mouse brain, using Kinobeads matrix 13 (la-S7 matrix for LRRK2) as a kinase capturing tool. Bound proteins were quantified by LCÀMS/MS (Supporting Information). pIC 50 values are represented as a heat map: Kinases that were captured by Kinobeads matrix but not competed by compound are represented as open circles. Kinases whose binding to Kinobeads was affected by free test compound are indicated by filled squares. pIC 50 values between 10 nM (dark blue) and 2 μM (light blue) were split into 10 equal bins and color-coded. Kinases that were not captured from a given cell source are not marked.
tissues. To determine the IC 50 for LRRK2 and many other kinases simultaneously, aliquots of mouse brain and kidney extracts were treated with various concentrations of a test compound, here sunitinib, or DMSO and were subsequently incubated with the la-sunitinib matrix. Proteins not blocked by free test compound were captured from the respective samples and quantified by chemical labeling of tryptic peptides with isobaric TMT tags, followed by tandem mass spectrometry analysis (LCÀMS/MS) of the combined peptide pools. 16 For identified protein targets, doseÀresponse curves and IC 50 values were computed from the decrease of reporter ion signals relative to the DMSO control (Supplementary Figure S2 , Table S1 , and Data Set). Sunitinib displayed a sub-μM IC 50 in this assay (Figure 1d ), but signal-tobackground ratios obtained with this matrix in a dot-blot screening assay was too low. We therefore generated a series of sunitinib analogues and tested their ability to prevent binding of mouse brain LRRK2 to the la-sunitinib matrix (Supplementary Figure S3) . Synthesis of a linkable analogue of S7 (la-S7), one of the most effective compounds, was successful ( Figure 1a ,d and synthetic procedures in Supporting Information). The la-S7 probe matrix improved the signal-to-background ratio (S/B > 5) of the dot blot array assay and enabled screening of a kinase-focused library of 127 compounds against mouse kidney lysate. One diaminopyrimidine screening hit (Figure 1e ), when tested at 3 μM, inhibited binding of mouse LRRK2 to la-S7 matrix by 90% and displayed an IC 50 of 0.19 μM. It was further optimized by using the la-S7 matrix-based dot blot array for potency measurement and the quantitative LCÀMS/MS-based assay for selectivity profiling. The lead compounds CZC-25146 and CZC-54252 resulted from this process (Figure 1e and synthetic procedures in Supporting Information).
Both leads are potent (IC 50 ≈ 10À30 nM) inhibitors of binding of mouse LRRK2 to la-S7 matrix in the chemoproteomics assay (Supplementary Table S3 and Supporting Information). Furthermore, they also inhibited activity of recombinant human wild type LRRK2 enzyme (IC 50 ≈ 1À5 nM) and of the G2019S mutant (IC 50 ≈ 2À7 nM) with low nanomolar potency, as assessed by a time-resolved fluorescence resonance energy transfer assay (Figure 2a,b) . In contrast, GW-5074 was 30-to 100-fold less potent in this assay (Supplementary Figure S4a) . Surprisingly, GW-5074 displayed very low potency in the la-S7 binding assay. Only incomplete doseÀresponse curves and no valid IC 50 's were obtained when concentrations as high as 100 μM were tested against both mouse kidney and human K562 extracts (Supplementary Figure S4b) , suggesting that species differences are not the reason for this discrepancy. Possibly the lack of potency of GW-5074 in a high protein assay (5 mg mL À1 protein per data point) can be attributed to the compound's noted lack of selectivity and multiple binding modes resulting in low free concentrations available for LRRK2 binding.
High selectivity, particularly against neuronal kinases, was a key objective of this study. Consequently, we profiled the selectivity of CZC-25146 and CZC-54252 against mouse brain, human HeLa, and mixed human Jurkat and Ramos cell extracts by quantitative LCÀMS/MS utilizing la-S7 matrix or an established affinity matrix that contains seven immobilized nonselective compounds ("Kinobeads") and therefore provides a comprehensive coverage of the kinome. 13 We determined IC 50 's (assay range 10 nM to 2 μM) for 184 different protein kinases and one lipid kinase. Whereas the 4-chloro-diaminopyrimidine CZC-54252 exhibited good selectivity and potently inhibited binding of only 10 human or mouse kinases, the 4-fluoro-diaminopyrimidine CZC-25146 displayed a very clean profile (Figure 2c and Supplementary Data Set). It inhibited only five kinases (PLK4, GAK, TNK1, CAMKK2, and PIP4K2C) with high potency, none of which have been classified as predictors of genotoxicity or hematopoietic toxicity. 18, 19 Furthermore, CZC-25146 did not cause cytotoxicity in human cortical neurons at concentrations below 5 μM over a seven-day treatment in culture (Supplementary Figure S5) , nor did it block neuronal development (assessed as average neurite length or number of branchpoints) in vitro (Figures 3 and 4) . Follow-up studies revealed that CZC-25146 possesses favorable pharmacokinetic properties, such as a volume of distribution of 5.4 L kg À1 and a clearance of 2.3 L h À1 kg À1 (Supplementary Table S4 ), which render it suitable for in vivo studies.
Next, we addressed the question of whether selective LRRK2 inhibition protects against mutant LRRK2-induced neuronal toxicity to a similar extent as non-selective inhibition with GW-5074 did in an earlier study. 7 Since both CZC-25146 and CZC-54252 displayed poor brain penetration (∼4%) in our pharmacokinetics studies, we turned to in vitro models to address this question. Toward this end, we overexpressed G2019S LRRK2 and R1441C LRRK2 in primary rodent cortical neurons. Both LRRK2 mutants caused cell injury, as assessed by neurite retraction and overt rounding up of the cells (Figure 3a,b) . Moreover, mutant LRRK2 triggered neuronal death, as assessed in a TUNEL assay measuring DNA fragmentation (Figure 3c ). In contrast, overexpression of eGFP or the kinase-dead double mutant G2019S/D1994A inflicted neither neuronal injury nor death, thus corroborating earlier studies 7, 20, 21 (Figure 3aÀc ). The most selective LRRK2 inhibitor, CZC-25146, attenuated G2019S LRRK2-induced neuronal injury and death in a concentrationdependent manner with an EC 50 of ∼100 nM. It completely blocked G2019S LRRK2 and R1441C-induced toxicity at higher concentrations (Figure 3d,e) , suggesting that inhibition of LRRK2 was sufficient for full neuroprotection in vitro. Since the efficacy of a LRRK2 inhibitor had never before been investigated in a human model of mutant LRRK2-induced toxicity, we established a neurite morphology assay using primary human cortical neurons. 22 We transfected cultured cells with GFP and either WT or mutant LRRK2 and subsequently measured average neurite length and branchpoint counts by computer-aided morphometry (Figure 4a ). Similar to rodent neurons (Figure 3aÀc ), overexpression of G2019S or R1441C mutant LRRK2 in human neurons resulted in cell injury, as assessed by a significant decrease in average neurite length. Kinase activity was required for this detrimental effect, since the kinase-deficient K1906 M LRRK2 as well as the G2019S/K1906M and R1441C/K1906M double mutants showed no toxicity (Figure 4b ). Lack of toxicity observed with the latter mutant confirms the notion that even in LRRK2 protein carrying a mutation in the Roc domain, it is the kinase domain that controls toxicity and overall function.
2 G2019S LRRK2-induced human neuronal injury was attenuated by CZC-25146 with an EC 50 of ∼4 nM (EC 50 CZC-54252, 1 nM) and fully reversed to wild type levels by both compounds at concentrations as low as 8 nM (1.6 nM for CZC-54252) (Figure 4c,d) . In human cortical neurons, no overt cytotoxicity was seen in the efficacious concentration range (only at 5 μM for CZC-25146 and g1 μM for CZC-54252) (Supplementary Figure S5) .
In summary, we have developed a potent, selective, cellpenetrant, and metabolically stable LRRK2 lead compound. Employing this small molecule inhibitor in the first study conducted to date in cultured primary human neurons, we have demonstrated that LRRK2 inhibition potently attenuates degeneration of human neurons induced by the mutant enzyme in vitro.
This key result of our study suggests that selective inhibition of LRRK2 is sufficient for the neuroprotective effect observed in earlier studies with non-selective inhibitors such as GW-5074. 7 Cell culture and in vivo studies performed with non-selective inhibitors are notoriously difficult to interpret. It is hardly feasible to test all possible mechanisms of action of a non-selective inhibitor; in case of GW-5074 this would imply testing of Raf1-, B-Raf-, 9 and allosteric glutamate dehydrogenase inhibition 10 and likely others. 11 Lee et al. 7 utilized another commercially available Raf1 inhibitor, ZM336372, to address the question of whether the mechanism of GW-5074 neuroprotection involved Raf1 kinase. ZM336372, however, is not a potent B-Raf inhibitor, and its function in cells has been debated. 23, 24 Use of our selective LRRK2 inhibitor resolves this dilemma and suggests that selective LRRK2 inhibition could indeed be a promising new paradigm for Parkinson's disease therapy. Furthermore, compounds such as CZC-25146 will enable precise molecular studies of LRRK2 signaling and toxicity in vitro.
It has been noted that LRRK2 expression is not restricted to medium-sized spiny striatal neurons, the key targets of the dopamine innervation. It is even more highly expressed in adult rat kidney and spleen, 25 but little is known about the function of wild type or mutant LRRK2 in these organs. A recent genomic study implicated the LRRK2 gene locus in the genetic susceptibility to Crohn's disease, a chronic inflammatory disease of the gut. 26 LRRK2 expression is increased in inflamed intestinal tissue in Crohn's disease, and the kinase may be involved in the production of reactive oxygen species during phagocytosis. 27 Analysis of functional consequences of LRRK2 inhibition in organs like kidney or blood with a precise and metabolically stable tool such as CZC-25146 will be of key importance for safety pharmacology in vitro and in vivo and thus for future drug discovery. Availability of selective, brain-impenetrant inhibitors may also prompt the in-depth investigation of possible therapeutic effects of selective LRRK2 inhibition in models of inflammatory disease in peripheral tissues in vivo.
Quantitative mass spectrometry-based chemical proteomics has been used effectively in the past for target identification, compound reprofiling, and mechanism of action studies.
13À15
Conceptually expanding this approach, with the successful development of this potent and selective LRRK2 inhibitor, we have demonstrated that quantitative chemoproteomics with targeted mass spectrometric analysis 14, 16, 28, 29 can generate IC 50 data that is robust. Our approach permits an understanding of structureÀactivity relationships that propels medicinal chemistry and provides a robust novel platform for lead optimization.
' METHODS Screen for LRRK2 Binding Compounds. Screening in a competition-binding format was performed as previously described, 14 with additional details provided in Supporting Information.
Quantitative LCÀMS/MS Profiling of Compounds. All profiling experiments were conducted as previously described 14, 15 with additional details in Supporting Information. PRIDE database (http:// www.ebi.ac.uk/pride): mass spectrometry data set accession numbers 0000À0000. (submission codes in preparation).
Primary Rat Cortical Neuronal Culture, Neuronal Viability, and TUNEL Assays. Primary cortical neuronal cultures were prepared from gestational day 15 fetal rats as previously described. 30 Additional details are provided in Supporting Information.
Primary Human Neuronal Culture and Neuronal Health Assay. Brain tissues from human fetuses (n = 5), ranging from 12 to 14 gestational weeks, were obtained through local agencies following all U.S. federal guidelines on fetal tissue research. Cerebral cortices were collected in oxygenized Hank's balanced saline solution (HBSS) with an average post-mortem delay of 15 min and transported on ice. All procedures were performed under sterile conditions. The cortex was first triturated in Hank's balanced saline solution (HBSS), then filtered through a cell strainer and treated with 0.05% Trypsin. After neutralization with 10% FBS, the dissociated cells were resuspended in MEM supplemented with B-27 (Invitrogen) and plated in poly-D-lysine coated plates at a density of 2.5 Â 10 4 well À1 . Rat cortical cultures were prepared similarly from embryonic day 18 (E18) fetal rats. All cultures were maintained in MEM/2% B-27/2 mM L-glutamine, with medium exchanged twice weekly. For characterization of LRRK2-induced neurite morphology change, various LRRK2 constructs and pmaxGFP (Amaxa) were cotransfected into neurons (20:1 ratio) with NeuroFECT (Genlantis) at DIV 14. To measure inhibitor effect, LRRK2 inhibitors or DMSO were also added at the indicated concentrations. The medium was exchanged on DIV17 with inhibitors replenished. On DIV 20, the cultures were harvested by fixation with 4% paraformaldehyde (PFA). Subsequent image acquisition and analysis were conducted on an ArrayScan VTI (Thermo Fisher Scientific) using the NeuronalProfiling V3.5 bioapplication. To monitor potential compound-mediated cytotoxicity,
